检索结果-南通市图书馆

Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China

引用

Biomedical and Environmental Sciences 2020年第12期33卷 893-905页

作者： MA yan ZHU Dong Shan CHEN Ren Bo shi Nan Nan liu Si Hong FAN yi Pin WU Gui hui yang Pu Ye BAI jiang feng CHEN Hong CHEN li ying feng Qiao GUO Tuan Mao HOU Yong HU Gui Fen HU Xiao Mei HU yun Hong HUANG jin HUANG Qiu Hua HUANG Shao Zhen ji liang jin Hai Hao LEI Xiao li Chun yan li min Qing li Qun Tang li Xian Yong liu Hong De liu jin Ping liu Zhang MA Yu Ting MAO Ya MO liu Fen NA hui wanG jing Wei SONG Fang li SUN Sheng wanG Dong Ting wanG ming Xuan wanG Xiao yan wanG yin Zhen wanG Yu Dong WU Wei WU Lan Ping XIAO yan Hua XIE Hai Jun XU Hong ming XU Shou Fang XUE Rui Xia yang Chun yang Kai Jun YUAN Sheng li ZHANG Gong Qi ZHANG jin Bo ZHANG lin Song zhao Shu Sen zhao wan ying ZHENG Kai ZHOU ying Chun ZHU Jun Teng ZHU Tian Qing ZHANG Hua min wanG yan Ping wanG Yong yan 无 Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical SciencesBeijing 100700China Centre for Health Management and Policy Research School of Public HealthCheeloo College of MedicineShandong UniversityJinan 250012ShandongChina Institute of Information on Traditional Chinese Medicine China Academy of Chinese Medical SciencesBeijing 100700China Department of Tuberculosis The Public Health Clinical Center of ChengduChengdu 610066SichuanChina Department of Infectious Disease Shaanxi Infectious Disease HospitalXi'an 610113ShaanxiChina Department of Infectious Disease Yulin Chinese Medicine HospitalYulin 719000ShaanxiChina President's Office The First Hospital of QiqiharQiqihar 161005HeilongjiangChina Department of Traditional Chinese Medicine Shangluo Central HospitalShangluo 726000ShaanxiChina Department of Traditional Chinese Medicine The People's Hospital of QitaiheQitaihe 154603HeilongjiangChina Department of Scientific Research Xianyang Central HospitalXianyang 712000ShaanxiChina Department of traditional Chinese medicine The First Affiliated Hospital of Anhui University of Traditional Chinese MedicineHefei 230012AnhuiChina Department of Infectious Disease Heping Hospital Affiliated to Changzhi Medical CollegeChangzhi 046000ShanxiChina Department of Traditional Chinese Medicine Langfang Hospital of Chinese MedicineLangfang 065000HeibeiChina Department of Traditional Chinese Medicine Xingtai Hospital of Chinese MedicineXingtai 054001HeibeiChina Department of Traditional Chinese Medicine The People's Hospital of Guangxi Zhuang Autonomous RegionNanning 168600GuangxiChina Department of Traditional Chinese Medicine The First People'sHospital of FangchenggangFangchenggang 538001GuangxiChina Department of Traditional Chinese Medicine Mianyang Hospital of Traditional Chinese MedicineMianyang 621000SichuanChina Department of Traditional Chinese Medicine Liuzhou People's HospitalLiuzhou 545006GansuChina Department of Traditional Chinese Medici

Objective Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the risk of COVID-19 remains *** A retrospective follow-up design was adopted. A total of 1,160 laboratory-confirmed patients were enrolled from nine provinces in China. Data on comorbidities were obtained from the patients’ medical records. Multivariable logistic regression models were used to estimate the odds ratio(OR) and 95% confidence interval(95% CI) of the associations between comorbidities(cardiometabolic or non-cardiometabolic diseases), clinical severity, and treatment outcomes of *** Overall, 158(13.6%) patients were diagnosed with severe illness and 32(2.7%) had unfavorable outcomes. Hypertension(2.87, 1.30–6.32), type 2 diabetes(T2 DM)(3.57, 2.32–5.49),cardiovascular disease(CVD)(3.78, 1.81–7.89), fatty liver disease(7.53, 1.96–28.96), hyperlipidemia(2.15, 1.26–3.67), other lung diseases(6.00, 3.01–11.96), and electrolyte imbalance(10.40, 3.00–26.10)were independently linked to increased odds of being severely ill. T2 DM(6.07, 2.89–12.75), CVD(8.47,6.03–11.89), and electrolyte imbalance(19.44, 11.47–32.96) were also strong predictors of unfavorable outcomes. Women with comorbidities were more likely to have severe disease on admission(5.46,3.25–9.19), while men with comorbidities were more likely to have unfavorable treatment outcomes(6.58, 1.46–29.64) within two *** Besides hypertension, diabetes, and CVD, fatty liver disease, hyperlipidemia, other lung diseases, and electrolyte imbalance were independent risk factors for COVID-19 severity and poor treatment outcome. Women with comorbidities were more likely to have severe disease, while men with comorbidities were more likely to have unfavorable treatment outcomes.

关键词： Comorbidities COVID-19 Severity Gender Age Treatment outcome

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants:a randomized phase 2 trial

引用

Signal Transduction and Targeted Therapy 2023年第2期8卷 672-682页

作者： Nawal Al Kaabi yun Kai yang Yu liang Ke Xu Xue feng Zhang yun Kang Yu Qin jin Jun Wei Hou jing Zhang Tian yang Salah Hussein Mohamed Saif ElDein Ze Hua Lei Hao Zhang Shuai Shao zhao ming liu Ning liu Xiang Zheng ji Guo Su Sen Sen yang Xiangfeng cong Yao Tan Wenwen Lei Xue Jun Gao zhiwei jiang hui wang Meng li Hanadi Mekki Mekki Walid Zaher Sally Mahmoud Xue Zhang Chang Qu Dan ying liu jing Zhang Mengjie yang Islam Eltantawy Peng Xiao Fu jie Shen jin Juan Wu Zi Bo Han li Fang Du Fang Tang shi Chen zhi jing Ma Fan Zheng Ya Nan Hou Xin Yu li Xin li zhao Nian wang jin liang yin Xiao yan Mao jin Zhang liang Qu yun Tao Zhang Xiao ming yang Guizhen Wu Qi ming li Sheikh Khalifa Medical City SEHAAbu DhabiUAE College of Medicine and Health Sciences Khalifa UniversityAbu DhabiUAE China National Biotec Group Company limited BeijingChina The Sixth Laboratory National Vaccine and Serum Institute(NVSI)BeijingChina National Engineering Center for New Vaccine Research BeijingChina National Institute for Viral Disease Control and Prevention Chinese Center for Disease Control and Prevention(China CDC)BeijingChina Clinical Medicine Office National Vaccine and Serum Institute(NVSI)BeijingChina Lanzhou Institute of Biological Products Company limited LanzhouChina Beijing Key Tech Statistical Consulting Co. LtdBeijingChina Beijing Institute of Biological Products Company limited BeijingChina Union 71 Abu DhabiUAE G42 Healthcare Abu DhabiUAE

An ongoing randomized,double-blind,controlled phase 2 trial was conducted to evaluate the safety and immunogenicity of a mosaic-type recombinant vaccine candidate,named NVSI-06-09,as a booster dose in subjects aged 18 years and older from the United Arab Emirates(UAE),who had administered two or three doses of inactivated vaccine BBIBP-CorV at least 6 months prior to *** participants were randomly assigned with 1:1 to receive a booster dose of NVSI-06-09 or *** primary outcomes were immunogenicity and safety against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)Omicron variant,and the exploratory outcome was cross-immunogenicity against other circulating *** May 25 and 30,2022,516 adults received booster vaccination with 260 in NVSI-06-09 group and 256 in BBIBP-CorV *** results showed a similar safety profile between two booster groups,with low incidence of adverse reactions of grade 1 or *** immunogenicity,by day 14 post-booster,the fold rises in neutralizing antibody geometric mean titers(GMTs)from baseline elicited by NVSI-06-09 were remarkably higher than those by BBIBP-CorV against the prototype strain(19.67 vs 4.47-fold),Omicron BA.1.1(42.35 vs 3.78-fold),BA.2(25.09 vs 2.91-fold),BA.4(22.42 vs 2.69-fold),and BA.5 variants(27.06 vs 4.73-fold).Similarly,the neutralizing GMTs boosted by NVSI-06-09 against Beta and Delta variants were also 6.60-fold and 7.17-fold higher than those by *** findings indicated that a booster dose of NVSI-06-09 was well-tolerated and elicited broad-spectrum neutralizing responses against divergent SARS-CoV-2 variants,including Omicron and its sub-lineages.

关键词： phase neutral spectrum

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline(updated version)

引用

Military Medical Research 2020年第3期7卷 249-282页

作者： ying-hui jin Qing-Yuan Zhan zhi-Yong Peng Xue-Qun Ren Xun-Tao yin lin Cai Yu-feng Yuan ji-Rong Yue Xiao-Chun Zhang Qi-Wen yang jianguang ji jian Xia yi-Rong li Fu-Xiang Zhou Ya-Dong Gao Zhui Yu feng Xu ming-li Tu li-ming Tan min yang Fang Chen Xiao-Ju Zhang Mei Zeng Yu Zhu Xin-Can liu jian yang Dong-Chi zhao Yu-feng Ding Ning Hou Fu-bing wang Hao Chen Yong-Gang Zhang Wei li Wen Chen Yue-Xian shi Xiu-zhi yang Xue-Jun wang yan-Jun Zhong ming-Juan zhao bing-hui li lin-Lu Ma Hao Zi Na wang yun-yun wang Shao-Fu Yu Lu-Yao li Qiao Huang Hong Weng Xiang-ying Ren li-Sha Luo Man-Ru Fan Di Huang Hong-yang Xue lin-Xin Yu jin-Ping Gao Tong Deng Xian-Tao Zeng Hong-Jun li Zhen-Shun Cheng Xiao-Mei Yao Xing-Huan wang Center for Evidence-Based and Translational Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China National Clinical Research Center for Respiratory Diseases China-Japan Friendship HospitalBeijing 100029China Department of Pulmonary and Critical Care Medicine China-Japan Friendship HospitalBeijing 10029China Leishenshan Hospital in Wuhan Wuhan 430200China Department of Critical Care Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China Institutes of Evidence-based Medicine and Knowledge Translation Henan UniversityKaifeng 475000HenanChina Department of Medical Imaging Guizhou Provincial People’s HospitalGuiyang 550002China Departments of Orthopedics Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery Zhongnan Hospital of Wuhan UniversityWuhan 430071China National Clinical Research Center for Geriatrics West China Hospital of Sichuan UniversityChengdu 610041China Department of Geriatrics West China Hospital of Sichuan UniversityChengdu 610041China Department of Radiology Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Clinical Laboratory Peking Union Medical College Hospital(PUMCH)Peking Union Medical CollegeChinese Academy of Medical Sciences(CAMS)Beijing 100730China Center for Primary Health Care Research Lund University and Region Skåne25002 MalmöSweden Emergency Center Zhongnan Hospital of Wuhan UniversityWuhan 403371China Department of Allergology Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Radiation and Medical Oncology Zhongnan Hospital of Wuhan UniversityWuhan 43071China Department of Critical Care Medicine Renmin Hospital of Wuhan UniversityWuhan 430060China Department of Emergency Medicine and Chest Pain Center Qilu Hospital of Shandong UniversityJinan 250002China Department of Respiratory and Critical Care Medicine Suizhou Central HospitalHubei University of MedicineSuizhou 441300HubeiChina Department of Clinic Pharmacy Second People’s Hospital of Huaihua Ci

The novel severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is the cause of a rapidly spreading illness,coronavirus disease 2019(COVID-19),affecting more than seventeen million people around the *** and treatment guidelines for clinicians caring for patients are *** the early stage,we have issued"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV)infected pneumonia(standard version)";now there are many direct evidences emerged and may change some of previous recommendations and it is ripe for develop an evidence-based *** formed a working group of clinical experts and *** steering group members proposed 29 questions that are relevant to the management of COVID-19 covering the following areas:chemoprophylaxis,diagnosis,treatments,and discharge *** searched the literature for direct evidence on the management of COVID-19,and assessed its certainty generated recommendations using the Grading of Recommendations,Assessment,Development and Evaluation(GRADE)*** were either strong or weak,or in the form of ungraded consensus-based ***,we issued 34 *** them,6 were strong recommendations for,14 were weak recommendations for,3 were weak recommendations against and 11 were ungraded consensus-based *** covered topics of chemoprophylaxis(including agents and Traditional Chinese Medicine(TCM)agents),diagnosis(including clinical manifestations,reverse transcription-polymerase chain reaction(RT-PCR),respiratory tract specimens,IgM and IgG antibody tests,chest computed tomography,chest X-ray,and CT features of asymptomatic infections),treatments(including lopinavirritonavir,umifenovir,favipiravir,interferon,remdesivir,combination of antiviral drugs,hydroxychloroquine/chloroquine,interleukin-6 inhibitors,interleukin-1 inhibitors,glucocorticoid,qingfei paidu decoction,lianhua qingwen granules/capsules,convalescent plasma,lung

关键词： COVID-19 SARS-CoV-2 Recommendation Chemoprophylaxis Diagnosis Treatment Discharge management Traditional Chinese medicine guideline

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Efficacy and safety of Shenyankangfu Tablet,a Chinese patent medicine,for primary glomerulonephritis:A multicenter randomized controlled trial

引用

Journal of Integrative Medicine 2021年第2期19卷 111-119页

作者： jie Wu Shu-wei Duan Hong-tao yang Yue-yi Deng Wei li Ya-ni He zhao-hui Ni Yong-li Zhan Shan lin zhi-yong Guo Jun Zhu jing-ai Fang Xu-sheng liu li-hua wang Rong wang Nian-song wang Xiao-hong Cheng li-qun He Ping Luo shi-ren Sun ji-feng Sun Ai-ping yin Geng-ru jiang Hong-yu Chen Wen-hu liu Hong-li lin Meng liang Lu Ma ming Chen li-qun Song jian Chen Qing Zhu Chang-ying Xing yun li ji-ning Gao Rong-shan li ying li Hao Zhang ying Lu Qiao-ling Zhou Jun-zhou Fu Qiang He Guang-yan Cai Xiang-mei Chen Department of Nephrology Chinese People’s Liberation Army General HospitalChinese People’s Liberation Army Institute of NephrologyState Key Laboratory of Kidney Diseases(2011DAV00088)National Clinical Research Center for Kidney DiseasesBeijing 100853China Department of Nephrology First Teaching Hospital of Tianjin University of Traditional Chinese MedicineTianjin 300192China Department of Nephrology Longhua HospitalShanghai University of Traditional Chinese MedicineShanghai 200032China Department of Nephrology Shandong University of Traditional Chinese Medicine Affiliated HospitalJinan 250011.Shandong ProvinceChina Department of Nephrology Daping HospitalArmy Medical UniversityChongqing 400042China Department of Nephrology Renji HospitalShanghai Jiao Tong UniversityShanghai 200127China Department of Nephrology Guang’anmen HospitalChina Academy of Traditional Chinese Medical SciencesBeijing 100053China Department of Nephrology Tianjin Medical University General HospitalTianjin 300052China Department of Nephrology Changhai Hospital of ShanghaiNaval Medical UniversityShanghai 200433China Department of Nephrology West China HospitalChengdu 610083Sichuan ProvinceChina Department of Nephrology First Affiliated Hospital of Shanxi Medical UniversityTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Guangdong Provincial Hospital of Chinese MedicineGuangzhou 510120Guangdong ProvinceChina Department of Nephrology Shanxi Medical University Second Affiliated HospitalTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Shandong Provincial HospitalJinan 250021Shandong ProvinceChina Department of Nephrology and Rheumatology Affiliated Sixth People’s HospitalShanghai Jiao Tong UniversityShanghai 200233China Department of Nephrology Shaanxi Traditional Chinese Medicine HospitalXi'an 710003Shaanxi ProvinceChina Department of Nephrology Shuguang HospitalShanghai University of Traditional Chinese MedicineShanghai 200021China Department of Nephrology Jilin University Se

Background:Shenyankangfu Tablet(SYKFT)is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney ***:This trial compared the efficacy and safety of SYKFT,for the control of proteinuria in primary glomerulonephritis patients,against the standard drug,losartan ***,setting,participants and intervention:This was a multicenter,double-blind,randomized,controlled clinical *** glomerulonephritis patients,aged 18-70 years,with blood pressure≤140/90 mmHg,estimated glomerular filtration rate(eGFR)>45 mL/min per 1.73 ㎡,and 24-hour proteinuria level of 0.5-3.0 g,were recruited in 41 hospitals across 19 provinces in China and were randomly divided into five groups:SYKFT,losartan potassium 50 mg or 100 mg,SYKFT plus losartan potassium 50 mg or 100 *** outcome measu res:The primary outcome was change in the 24-hour proteinuria level,after 48 weeks of ***:A total of 735 participants were *** percent decline of urine protein quantification in the SYKFT group after 48 weeks was 8.78%±2.56%(P=0.006)more than that in the losartan 50 mg group,which was 0.51%±2.54%(P=1.000)less than that in the losartan 100 mg *** with the losartan potassium 50 mg group,the SYKFT plus losartan potassium 50 mg group had a 13.39%±2.49%(Pmin from the baseline did not change statistically *** average change in TCM syndrome score between the patients who took SYKFT(-3.00[-6.00,-2.00])and who did not take SYKFT(-2.00[-5.00,0])was statistically significant(P=0.003).No obvious adverse reactions were observed in any ***:SYKFT decreased the proteinur

关键词： Herbal medicine,Chinese Shenyankangfu Tablet Primary glomerulonephritis Randomized controlled trial Double blind Double dummy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

The first data release(DR1) of the LAMOST regular survey

引用

Research in Astronomy and Astrophysics 2015年第8期15卷 1095-1124页

作者： A-li Luo Yong-Heng zhao Gang zhao li-Cai Deng Xiao-Wei liu yi-Peng jing Gang wang Hao-Tong Zhang jian-Rong shi Xiang-Qun Cui Yao-Quan Chu Guo-Ping li Zhong-Rui Bai Yue Wu yan Cai Shu-yun Cao Zi-Huang Cao Jeffrey L.Carlin Hai-Yuan Chen jian-Jun Chen Kun-Xin Chen li Chen Xue-Lei Chen Xiao-yan Chen ying Chen Norbert Christlieb jia-Ru Chu Chen-Zhou Cui yi-Qiao Dong bing Du Dong-Wei Fan Lei feng jian-Ning Fu Peng Gao Xue-Fei Gong Bo-Zhong Gu yan-Xin Guo Zhan-Wen Han Bo-liang He jin-liang Hou Yong-hui Hou Wen Hou Hong-Zhuan Hu Ning-Sheng Hu Zhong-Wen Hu zhi-ying Huo Lei jia Fang-Hua jiang Xiang jiang zhi-Bo jiang Ge jin Xiao Kong Xu Kong Ya-Juan Lei Ai-Hua li Chang-Hua li Guang-Wei li Hai-Ning li jian li Qi li Shuang li Sha-Sha li Xin-Nan li yan li yin-Bi li Ye-Ping li Yuan liang Chien-Cheng lin Chao liu Gen-Rong liu Guan-Qun liu zhi-Gang liu Wen-zhi Lu Yu Luo yin-Dun Mao Heidi Newberg ji-Jun Ni zhao-Xiang Qi Yong-Jun Qi shi-yin Shen Huo-ming shi jing Song yi-Han Song Ding-Qiang Su Hong-Jun Su Zheng-Hong Tang Qing-Sheng Tao Yuan Tian Dan wang Da-Qi wang feng-Fei wang Guo-min wang Hai wang Hong-Chi wang jian wang jia-Ning wang jian-ling wang jian-Ping wang Jun-Xian wang Lei wang Meng-Xin wang Shou-Guan wang Shu-Qing wang Xia wang Ya-Nan wang You wang Yue-Fei wang You-Fen wang Peng Wei ming-zhi Wei Hong Wu Ke-Fei Wu Xue-bing Wu Yu-Zhong Wu Xiao-Zheng Xing ling-Zhe Xu Xin-Qi Xu yan Xu Tai-Sheng yan De-Hua yang Hai-feng yang hui-Qin yang ming yang Zheng-Qiu Yao Yong Yu hui Yuan Hai-Bo Yuan Hai-Long Yuan Wei-min Yuan Chao Zhai En-Peng Zhang Hua-Wei Zhang jian-Nan Zhang li-Pin Zhang Wei Zhang Yong Zhang yan-Xia Zhang Zheng-Chao Zhang ming zhao Fang Zhou Xu Zhou jie Zhu Yong-Tian Zhu Si-Cheng Zou Fang Zuo National Astronomical Observatories Chinese Academy of Sciences Department of Astronomy Peking University Shanghai Astronomical Observatory Chinese Academy of Sciences Nanjing Institute of Astronomical Optics & Technology National Astronomical ObservatoriesChinese Academy of Sciences University of Science and Technology of China Department of Physics Applied Physics and AstronomyRensselaer Polytechnic InstituteTroyNY 12180USA Department of Physics and Astronomy Earlham CollegeRichmondIN 47374USA Universitt Heidelberg Zentrum für AstronomieLandessternwarteKnigstuhl 1269117 HeidelbergGermany Department of Astronomy Beijing Normal University yunnan Observatories Chinese Academy of Sciences Purple Mountain Observatory Chinese Academy of Sciences

The Large sky Area Multi-Object Fiber Spectroscopic Telescope（LAMOST） general survey is a spectroscopic survey that will eventually cover approximately half of the celestial sphere and collect 10 million spectra of stars, galaxies and QSOs. Objects in both the pilot survey and the first year regular survey are included in the LAMOST DR1. The pilot survey started in October 2011 and ended in June 2012, and the data have been released to the public as the LAMOST Pilot Data Release in August 2012. The regular survey started in September 2012, and completed its first year of operation in June 2013. The LAMOST DR1 includes a total of 1202 plates containing 2 955 336 spectra, of which 1 790 879 spectra have observed signalto-noise ratio（SNR） ≥ 10. All data with SNR ≥ 2 are formally released as LAMOST DR1 under the LAMOST data policy. This data release contains a total of 2 204 696 spectra, of which 1 944 329 are stellar spectra, 12 082 are galaxy spectra and 5017 are quasars. The DR1 not only includes spectra, but also three stellar catalogs with measured parameters： late A,FGK-type stars with high quality spectra（1 061 918 entries）, A-type stars（100 073 entries）, and M-type stars（121 522 entries）. This paper introduces the survey design, the observational and instrumental limitations, data reduction and analysis, and some caveats. A description of the FITS structure of spectral files and parameter catalogs is also provided.

关键词： techniques: spectroscopic survey—data release—catalog

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

The Large Sky Area Multi-Object Fiber Spectroscopic Telescope (LAMOST)

引用

Research in Astronomy and Astrophysics 2012年第9期12卷 1197-1242页

作者： Xiang-Qun Cui Yong-Heng zhao Yao-Quan Chu Guo-Ping li Qi li li-Ping Zhang Hong-Jun Su Zheng-Qiu Yao Ya-Nan wang Xiao-Zheng Xing Xin-Nan li Yong-Tian Zhu Gang wang Bo-Zhong Gu A-li Luo Xin-Qi Xu Zhen-Chao Zhang Gen-Rong liu Hao-Tong Zhang De-Hua yang Shu-yun Cao Hai-Yuan Chen jian-Jun Chen Kun-Xin Chen ying Chen jia-Ru Chu Lei feng Xue-Fei Gong Yong-hui Hou Hong-Zhuan Hu Ning-Sheng Hu Zhong-Wen Hu Lei jia Fang-Hua jiang Xiang jiang Zi-Bo jiang Ge jin Ai-Hua li yan li Ye-Ping li Guan-Qunliu zhi-Gang liu Huo-ming shi Zheng-Hong Tang Qing-Sheng Tao Xiang-yan Yuan Chao Zhai jing Zhang yan-Xia Zhang Yong Zhang ming zhao Fang Zhou Guo-Hua Zhou jie Zhu Si-Cheng Zou National Astronomical Observatories Chinese Academy of Sciences Beijing 100012 China yzhao @ *** Nanjing Institute of Astronomical Optics and Technology National Astronomical ObservatoriesChinese Academy of Sciences Nanjing 210042 China University of Science and Tecfinologyof China Hefei 230026 China Shanghai Astronomical Observatory Chinese Academy of Sciences Shanghai 200030 China Institute of Architecture Design and Research Chinese Academy of Sciences Beijing 100190China

The Large Sky Area Multi-Object Fiber Spectroscopic Telescope (LAMOST, also called the Guo Shou jing Telescope) is a special reflecting Schmidt telescope. LAMOST’s special design allows both a large aperture (effective aperture of 3.6 m–4.9 m) and a wide field of view (FOV) (5°). It has an innovative active reflecting Schmidt configuration which continuously changes the mirror’s surface that adjusts during the observation process and combines thin deformable mirror active optics with segmented active optics. Its primary mirror (6.67m×6.05 m) and active Schmidt mirror (5.74m×4.40 m) are both segmented, and composed of 37 and 24 hexagonal sub-mirrors respectively. By using a parallel controllable fiber positioning technique, the focal surface of 1.75 m in diameter can accommodate 4000 optical fibers. Also, LAMOST has 16 spectrographs with 32 CCD cameras. LAMOST will be the telescope with the highest rate of spectral acquisition. As a national large scientific project, the LAMOST project was formally proposed in 1996, and approved by the Chinese government in 1997. The construction started in 2001, was completed in 2008 and passed the official acceptance in June 2009. The LAMOST pilot survey was started in October 2011 and the spectroscopic survey will launch in September 2012. Up to now, LAMOST has released more than 480 000 spectra of objects. LAMOST will make an important contribution to the study of the large-scale structure of the Universe, structure and evolution of the Galaxy, and cross-identification of multiwaveband properties in celestial objects.

关键词： techniques: wide field telescope - active optics - multi fiber - spectroscopy survey - data reduction

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma(2022 version)

引用

Journal of Clinical and Translational Hepatology 2023年第7期11卷 1553-1564页

作者： Han wang Jun Chen Xin Zhang Xia Sheng Xiao-yan Chang jie Chen min-Shan Chen hui Dong Guang-jie Duan He-Ping Hu zhi-Yong Huang Wei-Dong jia Xiao-Qing jiang Dong Kuang Shan-Shan li Zeng-Shan li Chang-li Lu Shu-Kui Qin Xue-Shan Qiu li-Juan Qu Chun-Kui Shao feng Shen Guo-ming shi Su-Sheng shi Yu-Jun shi hui-Chuan Sun Xiao-Dong Teng bin wang Zhan-Bo wang Tian-Fu Wen jia-Mei yang Qiao-Qiao yang Sheng-Long Ye Hong-Fang yin Zhen-Gang Yuan jing-Ping yun feng-lin Zang Hong-Qi Zhang li-Hong Zhang jing-min zhao jian Zhou Wei-Xun Zhou jia Fan Xiao-Ping Chen wan Yee Lau Yuan ji Wen-ming cong Chinese Society of liver Cancer of Chinese Anti-Cancer Association Digestive Disease Group of Chinese Society of Pathology,Chinese Medical Association Chinese Society of Pathology of Chinese Anti-Cancer Association Hepatic Surgery Group of Chinese Society of Surgery,Chinese Medical Association Biliary Tract Tumor Committee of China Anti-Cancer Association Chinese Society of Clinical Oncology IDepartment of Pathology Eastern Hepatobilary Surgery HospitalNaval Medical UniversityShanghaiChina Department of Pathology the Affiliated Drum Tower HospitalNanjing University Medical SchoolNanjingJiangsuChina Department of Pathology Zhongshan HospitalFudan UniversityShanghaiChina Department of Pathology Minhang HospitalFudan Uni-versityShanghaiChina Department of Pathology Peking Union Medical College HospitalChinese Academy of Medical Sci-ences and Peking Union Medical CollegeBeijingChina Department of liver Surgery Sun Yat-Sen University Cancer CenterGuangzhouGuangdongChina Department of Pathology The First Affiliated HospitalArmy Medical UniversityChongqingChina Department of Hepatobiliary Medicine Eastern Hepatobiliary Surgery HospitalNaval Medical UniversityShanghaiChina Hepatic Surgery Center Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWu-hanHubeiChina Department of General Surgery The First Affliated Hospital of USTCDivision of Life Science and Medi-cineUniversity of Science and Technology of ChinaHefeiAnhuiChina Department of Biliary Surgery I Eastern Hepatobil-iary Surgery HospitalNaval Medical UniversityShanghaiChina Department of Pathology Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubeiChina Department of Pathology The First Afiliated Hospital of Zhengzhou UniversityZhengzhou UniversityZhengzhouHenanChina Department of Pathology Xijing Hospi-talAir Force Medical UniversityXi'anShaanxiChina Department of Pathology West China HospitalSichuan UniversityChengduSichuanChina Cancer Center of jinling Hospital Nanjing University of Chinese MedicineNanjingJiangsuChina Department of Pathology The First Affiliated HospitalChina Medical UniversityShenyangLiaoningChina Department of Pathology The 900 Hospital of the Chinese People's Liberation Army Joint Logistics TeamFuzhouFujianChina Department of Pathology The Third Affiliated HospitalSun Yat-Sen UniversityGuangz

Intrahepatic cholangiocarcinoma(iCCA)can originate from the large bile duct group(segment bile ducts and area bile ducts),small bile duct group(septal bile ducts and interlobular bile ducts),and terminal bile duct group(bile ductules and canals of Hering)of the intrahepatic biliary tree,which can be histopathological corresponding to large duct type iCCA,small duct type iCCA and iCCA with ductal plate malformation pattern,and cholangiolocarcinoma,*** challenge in pathological diagnosis of above subtypes of iCCA falls in the distinction of cellular morphologies,tissue structures,growth patterns,invasive behaviors,immunophenotypes,molecular mutations,and surgical *** these reasons,this expert consensus provides nine recommendations as a reference for standardizing and refining the diagnosis of pathological subtypes of iCCA,mainly based on the 5th edition of the World Health Organization Classification of Tumours of the Digestive System.

关键词： Intrahepatic cholangiocarcinoma Pathology Histological type Immunohistochemistry Molecular variation

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Prevalence, awareness, treatment, and control of hypertension in the non-dialysis chronic kidney disease patients

引用

Chinese Medical Journal 2013年第12期126卷 2276-2280页

作者： ZHENG ying CAI Guang-yan CHEN Xiang-mei FU Ping CHEN jiang-hua DING Xiao-qiang YU Xue-qing liN Hong-li liu jian XIE Ru-juan wanG li-ning NI zhao-hui liu Fu-you yiN Ai-ping XING Chang-ying wanG li shi Wei liu jian-she HE Ya-ni DING Guo-hua li Wen-ge WU Guang-li MIAO li-ning CHEN Nan SU Zhen MEI Chang-lin zhao jiu-yang GU Yong BAI yun-kai LUO hui-min liN Shan CHEN Meng-hua GONG li yang yi-bin yang Xiao-ping li ying wan jian-xin wanG Nian-song li Hai-ying XI Chun-sheng HAO li XU yan FANG jing-ai liu Bi-cheng li Rong-shan wanG Rong ZHANG jing-hong wanG jian-qin LOU Tan-qi SHAO feng-min MEI feng liu zhi-hong YUAN Wei-jie SUN shi-ren ZHANG ling ZHOU Chun-hua CHEN Qin-kai jiA Shun-lian GONG zhi-feng GUAN Guang-ju XIA Tian ZHONG liang-bao Department of Nephrology State key Laboratory of Kidney Disease Chinese PLA General Hospital Beijing 100853 China Nephrology Institute of the Chinese People's liberation Army Chinese People's Liberation Army Key Laboratory of Nephrology Beijing 100853 China Department of Nephrology West China Hospital of Sichuan University Chengdu Sichuan 610041 China Department of Nephrology First Affiliated Hospital School of Medicine Zhejiang University Hangzhou Zhejiang 310003 China Department of Nephrology Zhongshan Hospital Fudan University Shanghai 200032 China Department of Nephrology First Affiiated Hospital of Sun Yat-sen University Guangzhou Guangdong 510080 China Department of Nephrology First Affiliated Hospital of Dalian Medical University Dalian Liaoning 116011 China Department of Nephrology First Affiliated Hospital of Xinjiang Medical University Urumqi Xinjiang 830054 China Department of Nephrology First Affiliated Hospital of Harbin Medical University Harbin Heilongjiang 150001 China Department of Nephrology First Afftiated Hospital of China Medical University Shenyang Liaoning 110001 China Department of Nephrology Renji Hospital School of Medicine Shanghai Jiao Tong University Shanghai 200025 China Department of Nephrology Second Xiangya Hospital Central South University Changsha Hunan 410000 China Department of Nephrology First Affiliated Hospital of Medical College Xi'an Jiaotong University Xi'an Shaanxi 710061 China Department of Nephrology First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital) Nanjing Jiangsu 210029 China Department of Nephrology Sichuan Provincial People's Hospital Chengdu Sichuan 610072 China Department of Nephrology Guangdong Provincial People's Hospital Guangzhou Guangdong 510030 China Department of Nephrology Affliated Xiehe Hospital Tongji Medical College Huazhong Science and Technology University Wuhan Hubei 430022 China Department of Nephrology Daping Hospital Third Military Medi

Background Data on the epidemiology of hypertension in Chinese non-dialysis chronic kidney disease （CKD） patients are *** aim of the present study was to investigate the prevalence,awareness,treatment,and control of hypertension in the non-dialysis CKD patients through a nationwide,multicenter study in *** The survey was performed in 61 tertiary hospitals in 31 provinces,municipalities,and autonomous regions in China （except Hong Kong,Macao,and Taiwan）.Trained physicians collected demographic and clinical data and measured blood pressure （BP） using a standardized *** was defned as systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg,and/or use of antihypertensive *** 〈140/90 mmHg and 〈130/80 mmHg were used as the 2 thresholds of hypertension *** multivariate logistic regression with adjustment for sex and age,we analyzed the association between CKD stages and uncontrolled hypertension in non-dialysis CKD *** The analysis included 8927 non-dialysis CKD *** prevalence,awareness,and treatment of hypertension in non-dialysis CKD patients were 67.3%,85.8%,and 81.0%,*** hypertensive CKD patients,33.1% and 14.1% had controlled BP to 〈140/90 mmHg and 〈130/80 mmHg,*** successive CKD stages,the prevalence of hypertension in non-dialysis CKD patients increased,but the control of hypertension decreased （P〈0.001）.When the threshold of BP 〈130/80 mmHg was considered,the risk of uncontrolled hypertension in CKD 2,3a,3b,4,and 5 stages increased 1.3,1.4,1.4,2.5,and 4.0 times compared with CKD 1 stage,respectively （P〈0.05）.Using the threshold of 〈140/90 mmHg,the risk of uncontrolled hypertension increased in advanced stages （P〈0.05）.Conclusions The prevalence of hypertension Chinese non-dialysis CKD patients was high,and the hypertension control was *** successive CKD stages,the risk of uncontrolled hypertension increased.

关键词： non-dialysis chronic kidney disease chronic kidney disease stages hypertension epidemiology

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Consensus statement on layout and delivery of automatic external defibrillator in China

引用

Journal of Hainan Medical University 2020年第15期26卷 18-23页

作者： Yu Cao Song Chen yan-Fen Chai Xiao-hui Chen Yu-Guo Chen Shao-Wen Cheng Wen-Wei Cheng Bang-Han Ding yang Deng jie Fu Bang-jiang Fang Mai-ying Fan li Gui Ping Gong Wei Guo Shu-bin Guo liang Huang ji-Yuan Han Zhong ji Xian-Fei ji Xin-Cai ji Hong-Xu jin Xin-Jun jiang wang-Xiang jiang jia-liang liu Xiao-Ran liu zhi liu Chuan-Zhu Lv feng Lu Tan-shi li Xin li Yong li Shang-Lun li Shuang-ming li Xiao-Gang li Bao-Jun li Pei-Wu li Chun-Sheng li zhi-Jun li Chang-Luo li Xiang-min li yin-Ping li Zong-Jun Lu Zu-Xun Lu Zhong-Qiu Lu zhi-Qian Luo Xiao-Xing liao jian-Bo Lei Tao Ma Yu Ma Yue-feng Ma Qing-Bian Ma lin-Hao Ma Jun-Qi Ma shi-Nan Nie jie-Miao Ou-yang Peng Peng Qiao Pei Shu-ming Pan Guo-Zhong Qing li-jie Qin Wu-ying Qiao Fei Shao Wei Song Xing-Yue Song Zhen-Ju Song Rong-Ju Sun De-Ya Shang Du-Juan Sha Gui-Lan Tao Guo-Gang Tian ying-Ping Tian jian-Guang Tian Chao-yang Tong Zi-Ren Tang Meng-Xiong Tang Guo-Ping Wu zhi wan Tao wang Xin wang Peng wang Zhong wang Tong wang Ri-Xing wang yi-Xin wang Xiao-Dan wang ling Wu Wei Wei Hua Xiang feng Xu Jun Xu jie Xu Miao-Rong Xie Shuo-Gui Xu Tie Xu feng Yu Wen yi li-Shan yang shi-jiao yan jin-jian Yao Shou-Chun yan Xue-Zhong Yu Xian-zhi Ye Xian-liang yan Fu-bing Zhou Rong-bin Zhou ming Zhou Qiang Zhou jin Zhou Ping Zhou Chang-Ju Zhu Hua-Dong Zhu ji-Hong Zhu Hong Zhang Mao Zhang Hua Zhang Na Zhang Guo-Qiang Zhang Guo-Xiu Zhang jin-Song Zhang Wen-Wu Zhang Wen-Zhong Zhang jian-feng Zhang yi-min Zhu Jun Zeng Yuan Zheng zhi-jie Zheng Shen zhao yan zhao min zhao bin zhao Xiao-Dong zhao Xiao-jing zhao Hong-Ke Zeng Sheng-Qiang Zou The Chinese Society of Emergency Medicine Research Unit of Island Emergency Medicine Chinese Academy of Medical SciencesHainan Medical University Key Laboratory of Emergency and Trauma of ministry of Education Hainan Medical UniversityHaikouHainanChina Emergency and Trauma College Hainan Medical UniversityHaikouHainanChina Department of Emergency Hainan Clinical Research Center for Acute and Critical DiseasesThe Second Affiliated Hospital of Hainan Medical UniversityHaikouHainanChina Key Laboratory of Hainan Trauma and Disaster Rescue Key Laboratory of Trauma of Hainan Medical University

*** Sudden cardiac death(SCD)refers to sudden death due to a variety of cardiac *** is manifested as a sudden loss of consciousness,cardiac arrest,and respiratory arrest and generally shows early symptoms that are atypical and not easily detected[1].According to a recent study,nearly 544000 patients suffer from SCD every year in China[2].

关键词： cardiac death respiratory

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

International consensus on natural orifice specimen extraction surgery(NOSES)for gastric cancer(2019)

引用

Gastroenterology Report 2020年第1期8卷 5-10,I0001页

作者： Xu Guan Zheng liu Amjad Parvaiz Antonio Longo Avanish Saklani Ali AShafik jian-Chun Cai Charles Ternent lin Chen Cuneyt Kayaalp Fatih Sumer Fernanda Nogueira feng Gao Fang-Hai Han Qing-Si He Ho-Kyung Chun Chang-ming Huang Hai-yang Huang Rui Huang zhi-Wei jiang jim S Khan Joaquim Manuel da Costa Pereira JosephWNunoo-Mensah Jung Tack Son liang Kang Keisuke Uehara Ping Lan Le-Ping li Han liang bing-Rong liu Juan liu Dan Ma ming-yin Shen Mohammad Rashidul Islam Narimantas Evaldas Samalavicius Kai Pan Petr Tsarkov Xin-Yu Qin Ricardo Escalante Sergey Efetov Seung Kyu Jeong Suk-Hwan Lee Dong-hui Sun li Sun Tatiana Garmanova yan-Tao Tian Gui-Yu wang Guo-Jun wang Guo-Rong wang Xiao-Qiang wang William Tzu-liang Chen Woo Yong Lee Su yan Zu-li yang Gang Yu Pei-Wu Yu Dan zhao yun-shi Zhong jian-Ping wang Xi-Shan wang The International Alliance of NOSES Department of Colorectal Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingP.R.China Poole Hospital NHS Trust PooleUK European Center of Coloproctology and Pelvic Diseases-Multimedica Hospital MilanItaly Department of GI Surgical Oncology Tata Memorial HospitalMumbaiIndia Department of Colorectal Surgery Cairo UniversityCairoEgypt Department of Gastrointestinal Surgery Zhongshan Hospital of Xiamen UniversityXiamenFujianP.R.China Section of Colon and Rectal Surgery Creighton University School of MedicineOmahaNEUSA Department of General Surgery Chinese People’s Liberation Army General HospitalBeijingP.R.China Department of Gastrointestinal Surgery Inonu UniversityMalatyaTurkey Department of Surgery Hospital de BragaBragaPortugal Department of Colorectal Cancer Surgery the Second Affiliated Hospital of Harbin Medical UniversityHarbinHeilongjiangP.R.China Department of Gastroenterological Surgery Sun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhouGuangdongP.R.China Department of General Surgery Shandong University Qilu HospitalJinanShandongP.R.China Department of Surgery Kangbuk Samsung HospitalSungkyunkwan University School of MedicineSeoulSouth Korea Department of Gastric Surgery Fujian Medical University Union HospitalFuzhouFujianP.R.China Department of General Surgery Jiangsu Province Hospital of Traditional Chinese MedicineNanjingJiangsuP.R.China Department of Colorectal Surgery PortsmouthHospitals NHSTrustQueen Alexandra HospitalPortsmouthUK King’s College Hospital LondonUK Department of Colorectal Surgery The Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhouGuangdongP.R.China Division of Surgical Oncology Department of SurgeryNagoya University School of MedicineNagoyaJapan Department of Gastrointestinal Surgery Shandong Provincial Hospital Affiliated to Shandong UniversityJinanShandongP.R.China Department of Gastric Cancer

At present,natural orifice specimen extraction surgery(NOSES)has attracted more and more attention worldwide,because of its great advantages including minimal cutaneous trauma and post-operative pain,fast post-operative recovery,short hospital stay,and positive psychological ***,NOSES for the treatment of gastric cancer(GC)is still in its infancy,and there is great potential to improve its theoretical system and clinical ***,several key points including oncological outcomes,bacteriological concerns,indication selection,and standardized surgical procedures are raised with this innovative ***,it is necessary to achieve an international consensus to regulate the implementation of GC-NOSES,which is of great significance for healthy and orderly development of NOSES worldwide.

关键词： gastric cancer natural orifice specimen extraction surgery transanal specimen extraction transvaginal specimen extraction transoral specimen extraction consensus

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：